TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01252810
Drug: GE-145
Normalized name: 18F-GE-180
DrugBank: Flutriciclamide F-18 (DB15380)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GE-145-320 mg I/mL as a single iv. administration. Comparator agent Isovue (iopamidol) 370 mg I/mL as a single iv. administration.
Study: NCT01548924
Drug: Dovitinib
Normalized name: Dovitinib
DrugBank: Dovitinib (DB05928)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally Dovitinib once a day and a five-day regimen of administration and then two days resting, in cycles of 28 days.
Study: NCT01548924
Drug: Dovitinib + Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Paclitaxel (80 mg/m2) : 1, 8, 15 and 21.~* Dovitinib (100 mg, 200 mg,300 mg, 400 mg or500 mg; it depends on the level of the Phase 1 study in each patient): five days of treatment / two days off.~Each cycle will last for 28 days.
Study: NCT01655927
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03427125
Drug: Tenapanor
Normalized name: Tenapanor
DrugBank: Tenapanor (DB11761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active Drug
Study: NCT03427125
Drug: Sevelamer Carbonate
Normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active control
Study: NCT04393246
Drug: EDP1815
Normalized name: EDP1815
DrugBank: EDP1815 (DB16486)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP1815 is an orally administered pharmaceutical preparation of a single strain of Prevotella histicola isolated from the duodenum of a human donor. EDP1815 is currently in phase 2 clinical development and has European and US approval to initiate a multinational psoriasis study.
Study: NCT04393246
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor. Dapagliflozin is licensed for use in the UK for treatment of Type II diabetes. Since this trial is evaluating Dapagliflozin in an unlicensed indication, it is being carried out under a Clinical Trial Authorisation (CTA)
Study: NCT04393246
Drug: Ambrisentan
Normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ambrisentan is an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA). Ambrisentan was approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and indicated for the treatment of pulmonary arterial hypertension.
Study: NCT02858713
Drug: Calcipotriene + Betamethasone Dipropionate
Normalized name: betamethasone dipropionate / calcipotriene Topical Cream
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received Calcipotriene + Betamethasone Dipropionate once daily when needed for the entire study period.
Study: NCT00411138
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin 50 mg/m2 i.v., 2 cycles during radiotherapy, 3 wks interval
Study: NCT00411138
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: carboplatin AUC 5, 4 cycles after completion of radiotherapy, 3 wks interval
Study: NCT00411138
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: paclitaxel 175 mg/m2, 4 cycles after completion of radiotherapy, 3 wks interval
Study: NCT02033148
Drug: icotinib hydrochloride
Normalized name: Nicotine
DrugBank: Icotinib (DB11737)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00351754
Drug: Isovue
Normalized name: Isovue-370
DrugBank: Iopamidol (DB08947)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00652795
Drug: Doxycycline Monohydrate
Normalized name: Doxycycline Monohydrate
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, 150 mg, single-dose
Study: NCT00652795
Drug: Monodox
Normalized name: Monodox
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules 50 mg (3 x 50 mg dose), single-dose
Study: NCT03671746
Drug: Saline Solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 10 ml of saline solution IV every 6 hours for their first 5 days of hospitalization
Study: NCT00345761
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 7.5 mg/kg(i.v.) on Day 1 of 1 cycle(3 weeks)
Study: NCT00345761
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130 mg/m2(i.v.) on Day 1 of 1 cycle(3 weeks)
Study: NCT01523418
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The treatment with Xarelto 10mg tablets should comply with the recommendations. Rivaroxaban 10mg OD, 6-10 hours post-op, provided hemostasis has been achieved, for a period of 2 weeks (TKR) \& 5 weeks (THR)
Study: NCT02798835
Drug: Adductor canal block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine in the adductor canal in PACU.
Study: NCT02798835
Drug: Adductor canal block with dexamethasone
Normalized name: Ivy Block
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine in the adductor canal along with 8mg dexamethasone IV in PACU.
Study: NCT02798835
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Used in spinal anesthetic
Study: NCT02798835
Drug: Ropivacaine 0.5% Injectable Solution
Normalized name: ROPivacaine 0.5% injectable solution
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthetic to be used by surgeon as local infiltration and by anesthesiologist in adductor canal block.
Study: NCT02798835
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: To be given intravenously at time of nerve block to one of the study arms.
Study: NCT01451489
Drug: FK506
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FK506:0.05-0.1mg/kg/d
Study: NCT03630939
Drug: ESR-114
Normalized name: Esreboxetine
DrugBank: Esreboxetine (DB12395)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESR-114 Topical Gel
Study: NCT00113971
Drug: epratuzumab
Normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01081145
Drug: Extended-release Guanfacine Hydrochloride
Normalized name: guanfacine Extended Release Oral Tablet
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The test product will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose between 1-7mg/day depending on age and weight.
Study: NCT00046995
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03684213
Drug: Control (Norepinephrine)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This intervention is aimed at assessing the vascular responsiveness to norepinephrine, an alpha 1-agonist, in white and black men and women across a series of ascending dose concentrations.
Study: NCT00979251
Drug: Oseltamivir Phosphate
Normalized name: Oseltamivir Phosphate
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oseltamivir Phosphate, q8h
Study: NCT00979251
Drug: ADS-8902
Normalized name: Stahist AD
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine Hydrochloride, Ribavirin administered with Oseltamivir Phosphate, q8h
Study: NCT00920855
Drug: bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bendamustine was administered to 3 cohorts of patients at escalating doses of 50 (cohort 1), 70 (cohort 2) and 90 mg/m\^2/dose (cohort 3). Doses were administered by intravenous (iv) infusion once daily on days 1 and 4 of each 28-day cycle. Each iv was administered over 60 minutes and followed the injection of bortezomib.~Bortezomib will be administered to patients at a dose of 1.0 mg/m2/dose as an iv push over 3 to 5 seconds followed by a standard saline flush or through a running iv line. Doses are to be administered to patients on days 1, 4, 8 and 11 of the 28-day cycle.
Study: NCT00920855
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib was administered at a dose of 1.0 mg/m\^2/dose as an intravenous (iv) push over 3 to 5 seconds followed by a standard saline flush or through a running iv line. Doses are to be administered on days 1, 4, 8 and 11 of each 28-day cycle.
Study: NCT03951207
Drug: Amlodipine/Atorvastatin 5/20mg
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine/Atorvastatin 5/20mg qd for 8 weeks
Study: NCT03399370
Drug: Inclisiran Sodium
Normalized name: inclisiran sodium
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
Study: NCT03907098
Drug: Endostar
Normalized name: Endostar
DrugBank: Endostar (DB11727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: an anti-angiogenesis drug
Study: NCT04414098
Drug: INC424 / Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. Ruxolitinib 5 mg orally every 12 hours during 14 days.~2. Total Follow-up time will be of 45 days.~3. The reduction of ruxolitinib dose will be considered in cases of drug-related cytopenias.~4. During hospitalization, clinical and laboratory evolution parameters will be recorded daily in the medical history of the patient and in the data collection table of the study. Upon patient's discharge, a follow-up will be conducted until day +45~5. During hospitalization, adverse events will be monitored daily by means of clinical assessment and laboratory data.~6. After discharge, monitoring of adverse events will continue during the outpatient follow-up.~7. Pro-inflammatory parameters will be assessed at baseline, after one week (day +7) and at the end of treatment (day +14)~8. Ruxolitinib will be associated to the standard of care for COVID-19 of each center.~9. In case of an adverse effect or a need to discontinue the treatment, ruxolitinib should be suspended.
Study: NCT02929485
Drug: Tolcapone
Normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tolcapone 200mg (single dose) administered at study visit
Study: NCT02929485
Drug: Bromocriptine
Normalized name: Bromocriptine
DrugBank: Bromocriptine (DB01200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Bromocriptine 1.25 mg (single dose) administered at study visit
Study: NCT01755949
Drug: Colchicine, 0.6 mg PO BID
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo
Study: NCT02147535
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg as a single dose followed by one blood sample 3 hours post-dose
Study: NCT04009317
Drug: TQ-B3139
Normalized name: TQS-168
DrugBank: TQS-168 (DB18108)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a multi-target protein kinase inhibitor.
Study: NCT04009317
Drug: Crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: a multi-target protein kinase inhibitor.
Study: NCT00902954
Drug: anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: anastrozole 1 mg qd
Study: NCT00902954
Drug: letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: letrozole 2.5 mg qd
Study: NCT00902954
Drug: exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: exemestane 25 mg qd
Study: NCT02120066
Drug: subretinal injection of tissue-plasminogen activator
DrugBank: Plasminogen (DB16701)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00539994
Drug: retapamulin
Normalized name: Retapamulin
DrugBank: Retapamulin (DB01256)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 200mg BID retapamulin 3 days
Study: NCT00539994
Drug: Retapamulin
Normalized name: Retapamulin
DrugBank: Retapamulin (DB01256)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 200mg BID retapamulin 5 days
Study: NCT00548574
Drug: SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00548574
Drug: Mesalazine
Normalized name: mesalazine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00356681
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab is a recombinant, humanized anti-VEGF monoclonal antibody.
Study: NCT00356681
Drug: AMG 706
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 706 is a small organic molecule that has been shown in preclinical pharmacology and PK studies to be a potent, oral, multi-kinase inhibitor with anti-angiogenic and anti-tumor activity achieved by selectively targeting all known VEGF, PDGF and Kit receptors.
Study: NCT00356681
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel is an antineoplastic agent that acts by promoting and stabilizing the polymerization of microtubules.
Study: NCT04036981
Drug: Botulinum toxin type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Injection of botulinum toxin A into the spastic elbow flexor muscle or muscles
Study: NCT03650491
Drug: FOR46
Normalized name: Fosamprenavir
DrugBank: Fosamprenavir (DB01319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46
Study: NCT02266355
Drug: Omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab 300 mg SQ every 2 weeks
Study: NCT02946034
Drug: Viekira Pak ± ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 12 weeks treatment with AbbVie Viekira Pak ± ribavirin
Study: NCT02946034
Drug: Mavyret
Normalized name: Mavyret
DrugBank: Pibrentasvir (DB13878)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8 or 12 weeks treatment with AbbVie Mavyret
Study: NCT00695071
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT00064714
Drug: AC2993 (exenatide)
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose-escalation beginning with 2.5 μg administered subcutaneously twice per day (BID); then to 2.5 μg four times a day (QID); then to 5 μg four times a day; then to 10 μg four times a day.
Study: NCT00064714
Drug: daclizumab (immunosuppressive)
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2 mg/kg intravenously infused over 30 minutes every month for 12 months
Study: NCT05184530
Drug: Evolocumab 140 MG/ML
Normalized name: evolocumab 140 MG/ML
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 140 mg per two weeks, subcutaneous injection
Study: NCT02249988
Drug: ABX203 therapeutic Hepatitis B vaccine treatment arm
Normalized name: Hepatitis B Vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02870283
Drug: Lithium
Normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02870283
Drug: Valproic Acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02870283
Drug: Carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03697655
Drug: Daratumumab 20 MG/ML [Darzalex]
Normalized name: daratumumab 20 MG/ML [Darzalex]
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab dose 16 mg/kg body weight to be administered as an IV infusion. treatment given until clinical progression or SPR but no longer than 73 weeks
Study: NCT00188604
Drug: sodium selenite
Normalized name: Sodium selenite
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02867566
Drug: Rituximab plus CHOP
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Six cycles. Rituximab: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vindesine: 4 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
Study: NCT03359174
Drug: All-trans retinoic acid
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed low dose of ATRA 10 mg twice daily for 24 weeks.
Study: NCT02401347
Drug: Talazoparib Tosylate
Normalized name: TALAZOPARIB TOSYLATE
DrugBank: Talazoparib (DB11760)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants receive Talazoparib tosylate at 1 mg by mouth daily.
Study: NCT00363636
Drug: Galiximab in combination with rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Galiximab (500mg/m2 IV) in combination with Rituximab (375 mg/m2 IV), weekly x 4
Study: NCT00363636
Drug: Rituximab in combination with placebo
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (375 mg/m2 IV) in combination with placebo, weekly x 4
Study: NCT01245452
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (8 mg/kg monthly from week 0 to 20)
Study: NCT03389191
Drug: Acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00264199
Drug: GLP-1
Normalized name: rGLP-1
DrugBank: rGLP-1 (DB05433)
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv. by weight (1.0 pmol/kg/min )
Study: NCT00209352
Drug: Acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00424840
Drug: Bortezomib 1.3 mg/m2
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Level I (every 21 day cycle, D8), 1.3 mg/m2:~Day 1: bevacizumab 15 mg/kg ,carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.3 mg/m2 Day 8 : bortezomib 1.3 mg/m2~Level II (every 21 day cycle):~Day 1: bevacizumab 15 mg/kg, carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.6 mg/m2 Day 8 : bortezomib 1.6 mg/m2~Level III(every 21 day cycle):~Day 1: bevacizumab 15 mg/kg, carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.8 mg/m2 Day 8 : bortezomib 1.8 mg/m2
Study: NCT00424840
Drug: Bortezomib 1.6 mg/m2
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Level II (every 21 day cycle, D8), 1.6 mg/m2
Study: NCT00415285
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00981968
Drug: Sitaxentan sodium/Placebo
DrugBank: Sitaxentan (DB06268)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 100 mg and 200 mg, tablet, single and multiple oral doses for 7 days
Study: NCT00981968
Drug: Sitaxentan sodium/Placebo
DrugBank: Sitaxentan (DB06268)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 100 mg and 200 mg, tablet, single oral dose
Study: NCT03461575
Drug: HU007
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cyclosporine 0.02%, trehalose 3%
Study: NCT00424840
Drug: Carboplatin AUC 6
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC6
Study: NCT00424840
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 15 mg/kg
Study: NCT00424840
Drug: Taxotere
Normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taxotere 70 + G-CSF
Study: NCT00006474
Drug: O6-benzylguanine
Normalized name: O6-benzylguanine
DrugBank: 6-O-benzylguanine (DB11919)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00949806
Drug: BNT (intradermal injection)
Normalized name: BNT-162A1
DrugBank: BNT-162A1 (DB16402)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with severe RLS will receive a one-time intradermal administration of BNT into the most symptomatic areas of both legs.~Injections will be distributed in a grid distribution pattern covering a total of 20 equidistant sites per symptomatic area. Each symptomatic area will receive a maximum 250 units of BNT (12.5 units per injection). The total BNT injected units should not exceed 1000 units per patient.
Study: NCT00006474
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03123666
Drug: GMCSF
Normalized name: Ad5/3-D24-GMCSF
DrugBank: ONCOS-102 (DB17274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM CSF (Sargamostatim-250mcg/M2) over 4 hour and inhalation of same dose by micronebulizer
Study: NCT03461575
Drug: Restasis
Normalized name: Restasis
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclosporine 0.05%
Study: NCT01557127
Drug: Sorafenib (Nexavar, BAY43-9006)
Normalized name: sorafenib 200 MG [Nexavar]
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients scheduled for treatment with sorafenib given in regular daily dose i.e. 800mg (400mg bid)
Study: NCT02543606
Drug: Nexium
Normalized name: Nexium
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: powder for injection/ infusion Esomeprazole 40mg
Study: NCT03461575
Drug: Moisview
Normalized name: NIACINAMIDE 2 g in 100 mL TOPICAL LIQUID [MOISTIE PURE ESSENCE]
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: trehalose 3%
Study: NCT01736891
Drug: Rasagiline
Normalized name: Rasagiline
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets, qd